<h1 id="influenza-to-treat-or-not-to-treat-">Influenza: To treat or not to treat?</h1>
<ul>
<li>After the 2009 H1N1 pandemic, the predominant seasonal influenza A strain is H1N1</li>
</ul>
<h2 id="antiviral-agents">Antiviral Agents</h2>
<p>Adamantanes class: <strong><span class="drug">Amantadine</span></strong>, <strong><span class="drug">Rimantidine</span></strong></p>
<ul>
<li>Active only against influenza A</li>
</ul>
<p>Neuroaminidase inhibitors class: <strong><span class="drug">Oseltamivir</span></strong> (Tamiflu), <strong><span class="drug">Zanamivir</span></strong> (Relenza) </p>
<ul>
<li>Active against influenza A and B </li>
</ul>
<h2 id="influenza-patients-at-high-risk-for-complications-e-g-bacterial-pneumonia-">Influenza patients at high risk for complications (e.g. bacterial pneumonia)</h2>
<ul>
<li>Age &lt; 5 years old (especially &lt; 2 years)</li>
<li>Age ≤ 18 years old on long-term aspirin</li>
<li>Age ≥ 65 years old</li>
<li>American Indian or Alaska Native ethnicity</li>
<li><p>Comorbidities</p>
<ul>
<li>Chronic pulmonary disease</li>
<li>Cardiovascular disease (excluding hypertension)</li>
<li>Renal, hepatic, hematologic, metabolic disorders (including DM)</li>
<li>Neurologic and neurodevelopment conditions (including seizures)</li>
</ul>
</li>
<li><p>Immunosuppressed (HIV or on immunosuppressive medications)</p>
</li>
<li>Morbid obesity (BMI ≥ 40 kg/m2)</li>
<li>Pregnancy or within 2 weeks postpartum</li>
<li>Residents of nursing homes or chronic-care facilities </li>
</ul>
<h2 id="cdc-recommendations">CDC Recommendations</h2>
<ol>
<li>Observational study with &gt;700 patients admitted with influenza showed that oseltamivir reduced mortality (hazard ratio=0.27) and earlier hospital discharge (hazard ratio=1.28).</li>
<li>Give antiviral treatment ASAP for outpatients with confirmed or suspected influenza who are at high risk for complications (see list above). Use clinical judgement.</li>
<li><strong><span class="drug">Oseltamivir</span></strong> may be used for treatment or chemoprophylaxis for infants &lt;1 year old.</li>
<li>Consider giving antiviral treatment for confirmed or suspected influenza WITHOUT risk factors for severe illness, if treatment can be started ≤ 48 hours of illness onset. Can reduce duration of uncomplicated influenza A and B illness by 1 day.</li>
<li>Clinicians should monitor local antiviral resistance surveillance data because resistance patterns may change over time.</li>
</ol>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm">Centers for Disease Control &amp; Prevention. Antiviral agents for the tx and chemoprophylaxis of influenza—rec’s of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2011;60:1-24.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21871233">Dugas AF, Rothman RE. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Ann Emerg Med. 2011;58(3):303-4.</a></li>
</ul>
